Biotech

Ibalizumab Long-Term Safety and Efficacy Data to be Presented at IDWeek 2017 in San Diego

MONTREAL, QUEBEC: ...

Microbix Announces First Shipment of Bioreactor Antigen

TORONTO, ONTARIO: Customer Validation of New Manufacturing Process Completed ...

Arch Biopartners Increases Non-Brokered Private Placement Financing

TORONTO, ONTARIO: ...

ANGLE Announces Co-Marketing Partnership With Qiagen

GUILDFORD, UNITED KINGDOM: ...

Critical Outcome Technologies Announces CEO to Co-chair Global Genes Rare Partnering & Investor Forum

LONDON, ONTARIO and BOSTON, MASSACHUSETTS: ...

Themis Bioscience: Innovate UK fördert Entwicklung von Chikungunya-Impfung. Phase III Studien im Blick.

Wien: Die weitere Entwicklung eines vielversprechenden Chikungunya-Impfstoffkandidaten durch Themis Bioscience wird jetzt mit 3 Mio. Pfund durch die britische Innovationsagentur, Innovate UK, unterstützt. ...

Angle PLC Announces New Research With Parsortix Demonstrates Ability to Identify Key Proteins Involved in Breast Cancer Cell Growth and Survival

GUILDFORD, UNITED KINGDOM: ...

VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program

CAMBRIDGE, MASSACHUSETTS: ...

VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit

CAMBRIDGE, MASSACHUSETTS: - IND-enabling data, including restimulation of CMV-specific T-cell immunity in Rhesus Macaques - Mechanistic data demonstrating VBI-1901 stimulates innate immunity - Data presentation Wednesday, Aug. ...

Microbix to Amend Share Purchase Warrant Terms

TORONTO, ONTARIO: ...